Other languages Brii Biosciences Limited

Equities

2137

KYG1645A1094

Market Closed - Hong Kong S.E. Other stock markets 04:08:27 2024-07-12 am EDT			5-day change	1st Jan Change
1.05 ^HKD	+5.00%		+1.94%	-53.95%

Jun. 10	Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference	MT
Jun. 07	Brii Biosciences Limited Announces New Data from Two Phase 2 Studies Evaluating BRII-179	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Brii Biosciences Presents Hepatitis B Drug Data at European Medical Conference	Jun. 10
Brii Biosciences Limited Announces New Data from Two Phase 2 Studies Evaluating BRII-179	Jun. 07
Brii Bio's Hepatitis B Drugs Get Breakthrough Therapy Designation in China	May. 15
Brii Biosciences Limited Announces Center for Drug Evaluation of the National Medical Products Administration of China Grants Breakthrough Therapy Designations for BRII-877 and BRII-835	May. 13
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22
VBI Vaccines Sells Rights to Hepatitis B Vaccine to Brii Biosciences	Feb. 14
Brii Biosciences to Buy Rights to Hepatitis B Vaccine from VBI	Feb. 14
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer	Jan. 03
PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023	Nov. 13
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B	23-09-06
Brii Biosciences Limited Announces Data from Interim Analysis of A Randomized, Placebo-Controlled and Double-Blinded Phase 2 Study of Brii-179	23-09-06
Brii Biosciences Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-22
Shionogi Inc. completed the acquisition of Qpex Biopharma, Inc. from Brii Biosciences Limited and Others.	23-07-30
Brii Biosciences Limited Announces Executive Changes	23-07-05
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties	23-07-05
Vir Biotechnology, VBI Vaccines Release Data Supporting Brii Biosciences Medical Assets in Treating Hepatitis B	23-06-26
Brii Biosciences Limited Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating BRII-297	23-05-31
Brii Biosciences' Loss Narrows Down in 2022	23-03-24
Brii Biosciences Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24
Six Hong Kong-listed firms say their deposits at SVB are immaterial	23-03-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Brii Biosciences Limited

Equities

2137

KYG1645A1094

Other languages

Filters